(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
16 October 2025 (16.10.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/217520 A1

(51) International Patent Classification:
C07D 401/14 (2006.01) *A61K 31/404* (2006.01)
C07D 209/04 (2006.01) *C07D 209/10* (2006.01)
C07D 209/50 (2006.01) *A61P 13/12* (2006.01)

(21) International Application Number:
PCT/US2025/024283

(22) International Filing Date:
11 April 2025 (11.04.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/633,420 12 April 2024 (12.04.2024) US

(71) Applicant: **JNANA THERAPEUTICS INC.** [US/US]; One Design Center Place, Suite 19-400, Boston, MA 02210 (US).

(72) Inventors: **VRATSANOS, George**; 264 Castle Drive, Englewood Cliffs, NJ 07024 (US). **VIADER, Andreu**; 504 Essex St, Hamilton, MA 01982 (US). **WOBST, Heike, Julia**; 8 9th St., Apartment 803, Medford, MA 02155 (US). **BROWN, Dean, G.**; 10 Williams Way, Hollis, NH 03049 (US).

(74) Agent: **GORDON, Dana, M.** et al.; Patent Group, Foley Hoag LLP, 155 Seaport Boulevard, Boston, MA 02210-2600 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report (Art. 21(3))*

WO 2025/217520 A1

(54) Title: TREATING CHRONIC KIDNEY DISEASE WITH A COMBINATION OF SLC6A19 AND SGLT2 INHIBITORS

(57) Abstract: Disclosed are methods for treating or preventing chronic kidney disease (CKD) or any one of a number of other therapeutic indications, comprising co-administering to a patient in need thereof an effective amount of a SLC6A19 inhibitor and an effective amount of a SGLT2 inhibitor.